A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 These Triplets Were Tired Of Being Mistaken For Each Other. Their... June 14, 2019 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 Load more HOT NEWS Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Reunión anual de la American Society of Clinical Oncology de 2021:... Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,...
